Safe use of Sunitinib in metastatic non-clear cell renal cell cancer in the setting of human immunodeficiency virus

Abstract

The introduction of targeted therapies has offered the promise of better survival outcomes for patients 
with metastatic renal cell carcinoma. Sunitinib malate, an oral, multitargeted tyrosine kinase inhibitor, is 
an important treatment option for patients with metastatic renal cell carcinoma. This case study 
explores the controversial use of sunitinib in a patient with a non-clear cell variant of renal cell 
carcinoma, also on treatment with combined antiretroviral treatment for a co-existing human 
immunodeficiency virus infection.